We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Wegovy improved functional class vs. placebo at 1 year ...
ORLANDO, Fla. — Women with heart failure with preserved ejection fraction (HFpEF) and obesity, with or without diabetes, derive the same benefit from the glucagon-like peptide 1 receptor agonist ...
Objective: To identify subgroups of heart failure patients who might benefit from biventricular pacing. Background: Cardiac resynchronization therapy (CRT) improves the quality of life, New York Heart ...
Please provide your email address to receive an email when new articles are posted on . Device-based therapy may be necessary for certain patients with NYHA class II/III heart failure with reduced ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback